PFS according to posttreatment MRD status by NGS. (A) PFS from the end of treatment (EOT) according to MRD status in BM by NGS. Fifty-seven patients had BM specimens available. Results were dichotomized as detectable vs undetectable, regardless of sensitivity. (B) PFS from the EOT according to MRD status (detectable vs undetectable) in PBMC by NGS. Twenty-nine patients had PBMC specimens available. Results were dichotomized as detectable vs undetectable, regardless of sensitivity. (C) PFS from the EOT according to MRD6 status (<10−6 vs ≥10−6) in BM. Fifty-three of 57 BM specimens were useful for this analysis; 4 were not included as MRD was undetectable, but sensitivity did not reach 10−6. (D) PFS from the EOT according to MRD status (<10−6 vs ≥10−6) in PBMC. Twenty-one of 29 PBMC specimens were useful for this analysis; 8 were not included as MRD was undetectable, but sensitivity did not reach 10−6. (E) PFS from the EOT according to MRD status (detectable vs undetectable) by NGS in BM and IGHV mutation status. (F) PFS from the EOT according to absolute MRD level. Fifty-three of 57 BM specimens were useful for this analysis; 4 were not included as MRD was undetectable, but sensitivity did not reach 10−6. Prog. free, progression free.